Clinical trials
Multiple Sclerosis, Chronic Progressive clinical trials
Below are recruiting multiple sclerosis, chronic progressive clinical trials, each written for real people, not researchers. We’re tracking 47 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06846281RecruitingPhase 3
Switching to remibrutinib from ocrelizumab for relapsing MS
This study tests a new oral medication called remibrutinib for people with relapsing MS who are currently on ocrelizumab. The goal is to see if switching to remibrutinib is safe and effective for controlling MS long-term.
Scottsdale, ArizonaAges 40–70 - NCT06617793RecruitingPhase 1/Phase 2
Testing YTB323 for active relapsing multiple sclerosis
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
Darlinghurst, New South WalesAges 18–60 - NCT07503873RecruitingPhase 2
Study of ublituximab injection for multiple sclerosis
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
BihaćAges 18–65 - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT07321093RecruitingPhase 3
A study of BCD-281 for relapsing-remitting MS
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
Nizhny NovgorodAges 18–55 - NCT03109288RecruitingPhase 1/Phase 2
Biomarker-guided combination treatment for residual multiple sclerosis activity
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
Bethesda, MarylandAges 18–120 - NCT06782724RecruitingPhase 2
Psilocybin therapy for distress in advanced illness
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
PragueAges 18 years+ - NCT07609719RecruitingPhase 4
Switching to Subcutaneous Ocrelizumab for Multiple Sclerosis
This study tests a new way to give ocrelizumab—a medicine that treats multiple sclerosis—as an injection under the skin instead of through an IV. It's for people already taking similar MS drugs who want or need to switch treatments.
Birmingham, AlabamaAges 18–65 - NCT05162638Enrolling by invitation
Immune study in MS and healthy adults using a special tube
This study compares immune (defense system) “profiles” between people with multiple sclerosis (MS) and healthy volunteers. It involves a thoracic duct cannulation procedure and several MRIs to see how immune cells behave and whether a specific immune pattern is different in MS.
Philadelphia, PennsylvaniaAges 18–40 - NCT07353216Recruiting
Testing ofatumumab for relapsing multiple sclerosis
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Guangzhou, GuangdongAges 18 years+ - NCT07337785RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Wuhan, HubeiAges 18–70 - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Palo Alto, CaliforniaAges 18–75 - NCT02795052Recruiting
Stem cell treatment trial for nerve injury
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
Westport, ConnecticutAges 18 years+ - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT06529406RecruitingPhase 4
Switching from B-cell therapy to ozanimod in MS
This study tests whether people with stable MS who have been on a B-cell depleting therapy for at least 2 years can safely switch to a daily pill called ozanimod. It aims to see if this switch keeps MS under control and may be more convenient.
Aurora, ColoradoAges 18 years+ - NCT05877963RecruitingPhase 3
Ublituximab treatment plan for relapsing multiple sclerosis
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Birmingham, AlabamaAges 18–65 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT05957913Enrolling by invitationPhase 2
Testing antiviral drugs to control Epstein-Barr virus in MS
This Phase 2 study tests whether certain antiviral medicines can reduce Epstein-Barr virus (EBV) activity. If you have multiple sclerosis and evidence of EBV infection, the results may help clarify new ways to target EBV-related disease activity.
Boston, MassachusettsAges 18 years+ - NCT06733922RecruitingPhase 4
Tracking MS changes with ofatumumab in active relapsing MS
This study looks at whether blood tests and eye-tracking tasks can show how well ofatumumab slows or stops MS damage. It's for people starting ofatumumab as part of their regular care who have active relapsing-remitting MS.
Calgary, AlbertaAges 18–99 - NCT06782464Recruiting
Freezing nerves for shoulder pain after stroke or brain injury
This trial tests if freezing certain nerves in the upper arm (cryoneurolysis) works as well as standard care for reducing shoulder pain and muscle tightness after a stroke or brain injury. It aims to improve function and ease caregiving tasks.
LuxembourgAges 18 years+ - NCT07509125Recruiting
Ultra-high resolution PET brain scans for aging, dementia, and psychosis
This study uses a new ultra-high resolution PET scanner to look at brain changes in healthy aging, dementia, ALS, movement disorders, and psychosis. It aims to better understand these conditions and improve imaging techniques.
Leuven, Vlaams-BrabantAges 18–90 - NCT06254469RecruitingPhase 3
PET scan study for memory decline with head injury or Alzheimer's risk
This trial uses a special PET scan tracer to see if it can predict who will get worse over time. It is for people with mild memory or thinking problems that may be linked to past head injuries or early Alzheimer's disease.
Evanston, IllinoisAges 45 years+ - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+
Hear when a new Multiple Sclerosis, Chronic Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple sclerosis, chronic progressive?
- Yes. Clin2 currently lists 47 recruiting multiple sclerosis, chronic progressive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis, chronic progressive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis, chronic progressive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis (MS) - Relapsing-remitting
- Relapsing Multiple Sclerosis
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.